Prevalence of drug-drug interactions in oncology patients enrolled on National Clinical Trials Network oncology clinical trials

BACKGROUND: Drug-drug interactions (DDIs) in subjects enrolling in clinical trials can impact not only safety of the patient but also study drug outcomes and data validity. This makes it critical to adequately screen and manage DDIs. The study objective was to determine the prevalence of DDIs involv...

Descripción completa

Detalles Bibliográficos
Autores principales: Marcath, Lauren A., Coe, Taylor D., Hoylman, Emily K., Redman, Bruce G., Hertz, Daniel L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249716/
https://www.ncbi.nlm.nih.gov/pubmed/30466416
http://dx.doi.org/10.1186/s12885-018-5076-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249716/
https://www.ncbi.nlm.nih.gov/pubmed/30466416
http://dx.doi.org/10.1186/s12885-018-5076-0

Ejemplares similares